Viracta Therapeutics, Atara Biotherapeutics, and AlloVir are the leading players in the global EBV treatment market. The launch of novel therapies in clinical development for disease management, as well as the development of basic research, clinical medicine, and new ideas related to the pathogenesis and clinical aspects of EBV-associated diseases, are expected to cause significant changes in the EBV treatment space during the study period (2019–2032).